Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled budesonide for prevention of respiratory complications in extremely preterm infants
IRCT20081021001378N16Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of budesonide in respiratory distress syndrome (RDS) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Need for surfactant and Incidence of respiratory distress syndrome complications. Started May 2024; status: recruiting.
02
Drugs
budesonide
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20081021001378N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20081021001378N16.